Health Care & Life Sciences » Biotechnology | Avax Technologies Inc.

Avax Technologies Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2003
2004
2005
2006
2007
Sales/Revenue
930.70
1,691.10
1,623.70
734.80
617.40
SG&A Expense
3,780.70
4,636.40
5,153.80
5,943.00
7,009.30
Non Operating Income/Expense
2.60
-
-
-
-
Interest Expense
34.80
131.00
-
-
-
Pretax Income
3,286.10
3,457.90
3,703.80
5,355.50
6,413.60
Consolidated Net Income
3,286.10
3,457.90
3,703.80
5,355.50
6,413.60
Net Income
3,286.10
3,457.90
3,703.80
5,355.50
6,413.60
Net Income After Extraordinaries
3,286.10
3,457.90
3,703.80
5,355.50
6,413.60
Net Income Available to Common
3,286.10
3,457.90
3,703.80
5,355.50
6,413.60
EPS (Basic)
0.19
0.12
0.07
0.09
0.05
Basic Shares Outstanding
17,503.20
29,409.40
54,818.80
61,415.00
118,913.40
EPS (Diluted)
0.19
0.12
0.07
0.09
0.05
Diluted Shares Outstanding
17,503.20
29,409.40
54,818.80
61,415.00
118,913.40
EBITDA
2,850.00
2,945.30
3,530.10
5,208.20
6,391.90
Non-Operating Interest Income
15.60
13.50
141.40
143.20
279.20

About Avax Technologies

View Profile
Address
2000 Hamilton Street
Philadelphia Pennsylvania 19130
United States
Employees -
Website http://www.avax-tech.com
Updated 07/08/2019
AVAX Technologies, Inc. operates as bio-technology company, which engages in the provision of development and commercialization of vaccine therapies and technologies for the treatment of cancer. It offers biological manufacturing services to biotechnology and pharmaceutical companies. The company was founded by Kenneth E.